Safety, Tolerability, Pharmacokinetics, and pharmacodynamics of YH35324, a novel Long-Acting High-Affinity IgETrap-Fc protein in subjects with Atopy: Results from the First-in-Human study

• Published in: International immunopharmacology Vol. 130; p. 111706
• Main Authors: Ye, Young-Min, Park, Jung-Won, Kim, Sae-Hoon, Cho, You Sook, Lee, Sook Young, Lee, Sae Young, Sim, Sujin, Song, Eunji, Kim, Bomin, Lee, Jieon, Kim, Su Kyung, Jang, Myoung Ho, Park, Hae-Sim
• Format: Journal Article
• Language: English
• Published: Elsevier B.V 30.03.2024
• Subjects: (6 max): Atopy; Allergy; anti-IgE antibody; IgE; Mast cell; Allergy; Mast cell; anti-IgE antibody; IgE; (6 max): Atopy
• DOI: 10.1016/j.intimp.2024.111706
• ISSN: 1567-5769; 1878-1705

•Treatment-emergent adverse events (TEAEs) were mainly grade 1 or 2.•No serious AEs, treatment discontinuation due to AEs, or anaphylaxis were reported.•YH35324 (0.3–9 mg/kg) showed a dose-proportional increase in Cmax and AUClast.•Serum-free IgE level was rapidly suppressed to a significant extent at all doses of YH35324.•YH35324 demonstrates favorable safety and therapeutic potential in atopic subjects. YH35324, a long-acting IgETrap-Fc fusion protein, is a novel therapeutic agent for immunoglobulin E (IgE)-mediated allergic diseases. This randomized, double-blind, placebo/active-controlled, single ascending dose Phase 1 study assessed the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of YH35324 in subjects with atopy. Eligible subjects were healthy subjects or atopic adults with mild allergic rhinitis, atopic dermatitis, food allergy, or urticaria, and a serum total IgE level of 30–700 IU/mL (Part A) or > 700 IU/mL (Part B). In Part A, 35 subjects in 5 cohorts received YH35324 (0.3, 1, 3, 6, and 9 mg/kg), 8 received omalizumab (300 mg), and 9 received placebo. In Part B, 8 subjects received YH35324 and 8 received omalizumab. Twenty subjects (38.5 %) in Part A (YH35324: 37.1 %, omalizumab: 50.0 %, placebo: 33.3 %) and 10 subjects (62.5 %) in Part B (YH35324: 100 %; omalizumab: 25.0 %) experienced treatment-emergent adverse events (TEAEs). TEAEs were mostly grade 1/2; no serious AEs, AE-related treatment discontinuation, or anaphylaxis were reported. YH35324 exhibited dose-proportional increase in Cmax and AUClast over the dose range of 0.3–9 mg/kg. YH35324 rapidly suppressed serum-free IgE levels to a significant extent (< 25 and < 82.8 ng/mL, both P < 0.05) and with longer duration than omalizumab. This study showed that YH35324 has a favorable safety profile and is effective in reducing serum-free IgE levels in subjects with atopic conditions.